Journal Article

DKFZ-2020-00220

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Postmenopausal hormone replacement therapy and colorectal cancer risk by molecular subtypes and pathways.

Amitay, E. (First author)DKFZ* ; Carr, P. R.DKFZ* ; Jansen, L.DKFZ* ; Alwers, E.DKFZ* ; Roth, W. ; Herpel, E. ; Kloor, M. ; Bläker, H. ; Chang-Claude, J.DKFZ* ; Brenner, H.DKFZ* ; Hoffmeister, M. (Last author)DKFZ*

2020
Wiley-Liss Bognor Regis

Abstract: Postmenopausal hormone replacement therapy (HRT) was found to be associated with lower risk of colorectal cancer (CRC). However, little is known regarding associations with molecular subtypes of CRC. The current study includes female participants of a large German population-based case-control study (922 CRC cases and 1,183 controls). Tumor tissue samples were analyzed for microsatellite instability (MSI), CpG island methylator phenotype (CIMP), BRAF and KRAS mutation status. Multivariable logistic regression models were used to assess the association of HRT use with molecular subtypes and pathways. Postmenopausal HRT use was overall associated with reduced risk of CRC (adjusted odds-ratio (aOR) 0.62, 95% confidence interval (CI) 0.50-0.76) and no major differences were observed for molecular subtypes or for tumor marker combinations representing molecular pathways. When stratified by median age (≤/>71 years) potentially stronger risk reductions were observed in the older group for subtypes showing MSI (OR = 0.36, 95%CI 0.17-0.76), BRAF mutation (OR = 0.40, 95%CI 0.30-0.83) and CIMP-high (OR = 0.40, 95%CI 0.21-0.73) and for CRC suggestive of the sessile serrated pathway (OR = 0.45, 95%CI 0.20-1.01). In conclusion, postmenopausal use of HRT was similarly associated with risk reduction of major molecular tumor subtypes and pathways of CRC. Potentially stronger risk reductions with CRC subtypes diagnosed at higher ages require confirmation and clarification from other studies. The current study extends the limited understanding of the mechanisms of HRT in CRC prevention. This article is protected by copyright. All rights reserved.

Note: 2020 Aug 15;147(4):1018-1026#EA:C070#LA:C070#

---

Contributing Institute(s):

1. C070 Klinische Epidemiologie und Alternf. (C070)
2. Präventive Onkologie (C120)
3. DKTK HD zentral (HD01)
4. C020 Epidemiologie von Krebs (C020)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2020

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---